Recent Quotes (30 days)

You have no recent quotes
chg | %

Hamilton Thorne Ltd.  

(Public, CVE:HTL)   Watch this stock  
Find more results for htl
0.000 (0.00%)
Delayed:   12:40PM EST
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.38 - 0.38
52 week 0.04 - 0.51
Open 0.38
Vol / Avg. 1,500.00/45,647.00
Mkt cap 22.22M
P/E 30.64
Div/yield     -
EPS 0.01
Shares 59.60M
Beta 3.04
Inst. own     -
Nov 25, 2014
Q3 2014 Hamilton Thorne Ltd Earnings Release

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 7.17% 1.67%
Operating margin 10.04% 5.44%
EBITD margin - 5.70%
Return on average assets 25.75% 6.04%
Return on average equity - -
CDP Score - -


100 Cummings Ctr Ste 465e
BEVERLY, MA 01915-6143
United States - Map
+1-978-9212050 (Phone)
+1-978-9210250 (Fax)

Website links


Hamilton Thorne Ltd. (HTL), is engaged in the development, manufacture and sale of precision laser and advanced image analysis systems for living cell applications in the fertility, stem cell, and developmental biology research markets. The Company sells its products through its direct sales force and through distributors to pharmaceutical companies, biotechnology companies, fertility clinics, hospitals, educational institutions and other commercial and academic research establishments worldwide. The Company had five lasers that have been introduced, with additional products in development. The Company�s Computer Assisted Sperm Analysis (CASA) image analysis systems are designed for study of reproductive cells in the animal and human infertility and reproductive toxicology fields. These systems assist researchers and clinicians in analyzing sperm motility and other characteristics in human fertility, toxicology and animal applications.

Officers and directors

Meg D. Spencer Chairman of the Board
David Wolf President, Chief Executive Officer, Director
Michael W. Bruns CPA Chief Financial Officer, Vice President - Finance
Age: 55
Diarmaid H. Douglas-Hamilton Corporate Secretary, Chief Technology Officer and Senior Vice-President - Research & Development of the Corporation, Director
Thomas Kenny Vice President - Engineering
Dean Gendron Independent Director
Bruno C. Maruzzo Independent Director
Age: 60
Robert J. Potter Independent Director
David B. Sable M.D. Independent Director
Daniel K. Thorne Independent Director
Age: 52